Resolution of acquired von Willebrand syndrome after transcatheter aortic valve implantation through a left transcarotid approach

Pozzi, Mattéo; Hanss, Michel; Petrosyan, A; Vedrinne, C.; Green, L.; Dementhon, Julie; Pizzighini, S.; Rioufol, Gilles; Finet, Gérard; Obadia, Jean‐François

doi:10.1016/j.ijcard.2014.07.267

Cited by 10 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 1987, King et al firstly reported the correction of bleeding tendency in 91 patients with calcific AS and Heyde syndrome after surgical aortic valve replacement (SAVR). 25 To date, many studies reported similar results 26,27 showing a reduction of bleeding tendency in > 90% of patients with angiodysplasia. 40 Transcatheter aortic valve replacement also leads to a restoration of vWF abnormalities 33 and a resolution of Heyde syndrome in patients at high risk for SAVR.…”

Section: Von Willebrand Factor In Valvular Heart Diseasementioning

confidence: 86%

Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement

et al. 2017

View full text Add to dashboard Cite

von Willebrand Factor (vWF) is a well-known mediator of hemostasis and vascular inflammation. Its dynamic modulation in the bloodstream, according to hemodynamic conditions, makes it an appealing biomarker in patients with valvular heart disease (VHD). Recent studies highlight the close connection between vWF and VHD, with possible implications in the pathogenesis of VHD, promoting valve aging and calcification or favoring the development of infective endocarditis. Moreover, vWF has been recently proposed as a new diagnostic and prognostic tool in patients with valve stenosis or regurgitation, showing a strict correlation with severity of valve disease, outcome, and bleeding (Heyde syndrome). A novel role for vWF is also emerging in patients undergoing percutaneous or surgical valve repair/replacement to select and stratify patients, evaluate periprocedural bleeding risk, and detect procedural complications. We also report our single-center experience, suggesting, for the first time, possible clinical implications for vWF in percutaneous mitral valve repair (MitraClip). This review summarizes recent advances in the role of vWF in VHD with an updated overview going from bench to operating room.

show abstract

Section: Von Willebrand Factor In Valvular Heart Diseasementioning

confidence: 86%

Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In our review of the English medical literature, we identified 15 cases of Heyde’s syndrome treated with trans-catheter aortic valve replacement from case reports, prospective and retrospective studies [11–16]. Totally, 5/15 cases were followed up by repeating hemostaseologic testing, 7 days after the trans-catheter aortic valve replacement [11,12].…”

Section: Discussionmentioning

confidence: 99%

A case of recurrent obscure gastrointestinal bleeding: Heyde’s syndrome – case report and review

Ramachandran

Uqdah

Jani

2018

Journal of Community Hospital Internal Medicine Perspectives

View full text Add to dashboard Cite

show abstract

“…aortic and mitral valve stenosis as well as mitral valve regurgitation 11 . VWF deficiency can be completely reversed after aortic valve replacement therapy 12 thus, vWF has been proposed as a new hemodynamic biomarker for monitoring surgical or percutaneous aortic valve replacement procedures 13‐15 …”

Section: Introductionmentioning

confidence: 99%

Acquired von Willebrand syndrome and factor VIII in patients with moderate to severe mitral regurgitation undergoing transcatheter mitral valve repair

Meindl

Paulus

Koller

et al. 2020

Clinical Cardiology

View full text Add to dashboard Cite

Background and Hypothesis The acquired von Willebrand syndrome (AvWS), which predisposes to bleeding events, is often related to valvular heart diseases. We investigated possible implications of AvWS and factor VIII levels in patients with moderate to severe mitral regurgitation (MR) undergoing transcatheter mitral valve repair (TMVR). Methods and Results 123 patients with moderate to severe MR were prospectively enrolled. Complete measurements of von Willebrand Factor activity (vWFAct), von Willebrand Factor antigen (vWFAg), and factor VIII expression before and 4 weeks after TMVR were available in 85 patients. At baseline, seven patients had a history of gastrointestinal bleeding, two patients suffered bleeding events during their hospital stay, and one patient had a bleeding 4 weeks after TMVR. Even though vWFAct, vWFAct/vWFAg ratio and vWFAg values did not change after TMVR, we observed a significantly lower vWFAct/vWFAg ratio in patients with primary MR as compared to patients with secondary MR both at baseline (p = 0.022) and 4 weeks following the TMVR procedure (p = 0.003). Additionally, patients with a mean mitral valve gradient ≥4 mmHg after TMVR had significantly lower vWFAct/vWFAg ratios as compared to patients with a mean mitral valve gradient <4 mmHg (p = 0.001). Conclusions MR of primary etiology was associated with lower vWFAct/vWFAg ratio, hinting toward HMWM loss due to shear stress caused by eccentric regurgitation jets. In addition, morphological changes leading to postprocedural transmitral gradients ≥4 mmHg were related to lower vWFAct/vWFAg ratio 4 weeks after the procedure. Alterations of the vWFAct/vWFAg ratio in turn did not translate into a greater risk for bleeding events.

show abstract

Resolution of acquired von Willebrand syndrome after transcatheter aortic valve implantation through a left transcarotid approach

Cited by 10 publications

References 8 publications

Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement

Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement

A case of recurrent obscure gastrointestinal bleeding: Heyde’s syndrome – case report and review

Acquired von Willebrand syndrome and factor VIII in patients with moderate to severe mitral regurgitation undergoing transcatheter mitral valve repair

Contact Info

Product

Resources

About